Amylin: difference between revisions
Diff·revision 11 → 12·01:42, 4 Jan 2025
Difference between revision 11 and revision 12 of Amylin. 4 lines changed; the page grew by 132 bytes.
| Revision 11 — 11:25, 20 Dec 2024 MazdutideMads (talk) add the receptor targets to the lead sentence 3,694 bytes +456 | Revision 12 — 01:42, 4 Jan 2025 CagriCass (talk) state plainly that the research-use-only form is not approved for human use 3,826 bytes +132 | ||
|---|---|---|---|
| 1 | {{Infobox compound | 1 | {{Infobox compound |
| 2 | | name = Amylin | 2 | | name = Amylin |
| + | 3 | | subtitle = Islet hormone | |
| 3 | | image = peptide-chain.svg | 4 | | image = peptide-chain.svg |
| 4 | | Also known as = Islet amyloid polypeptide (IAPP) | 5 | | Also known as = Islet amyloid polypeptide (IAPP) |
| ⋮ | ⋮ | ||
| 9 | | Plasma half-life = ≈13 minutes | 10 | | Plasma half-life = ≈13 minutes |
| 10 | | Notable property = Human sequence is amyloidogenic | 11 | | Notable property = Human sequence is amyloidogenic |
| + | 12 | <!-- Receptor --> | |
| + | 13 | | Target = Calcitonin receptor plus RAMP1/2/3 | |
| + | 14 | | Principal site = Area postrema | |
| 11 | }} | 15 | }} |
| 12 | 16 |